BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24006150)

  • 21. Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients.
    Al-Muqbel KM; Yaghan RJ; Al-Omari MH; Rousan LA; Dagher NM; Al Bashir S
    Nucl Med Commun; 2016 Jun; 37(6):593-601. PubMed ID: 26813990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT.
    Samarin A; Hüllner M; Queiroz MA; Stolzmann P; Burger IA; von Schulthess G; Veit-Haibach P
    Nucl Med Commun; 2015 Dec; 36(12):1165-73. PubMed ID: 26397999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer.
    Lee JW; Lee SM; Lee HS; Kim YH; Bae WK
    Ann Nucl Med; 2012 Oct; 26(8):627-33. PubMed ID: 22729551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV
    Azad GK; Cousin F; Siddique M; Taylor B; Goh V; Cook GJR
    Mol Imaging Biol; 2019 Aug; 21(4):781-789. PubMed ID: 30250989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
    Iagaru A; Mittra E; Dick DW; Gambhir SS
    Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (18)F-FDG-PET/CT findings in pancreatic metastasis.
    Hu S; Zhang J; Zuo C; Cheng C; Liu Q; Sun G
    Radiol Med; 2015 Oct; 120(10):887-98. PubMed ID: 25795439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
    Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients].
    Portilla-Quattrociocchi H; Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; de Arcocha Torres M; Medina-Quiroz P; del Castillo R; Rubio-Vassallo A; Carril JM
    Rev Esp Med Nucl; 2011; 30(1):2-7. PubMed ID: 21208693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of 18F-α-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer.
    Kaira K; Higuchi T; Sunaga N; Arisaka Y; Hisada T; Tominaga H; Oriuchi N; Asao T; Tsushima Y; Yamada M
    Anticancer Res; 2016 Dec; 36(12):6481-6490. PubMed ID: 27919971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disseminated osteomyelitis or bone metastases of breast cancer: (18)F-FDG-PET/CT helps unravel an unusual presentation.
    Mandegaran R; Debard A; Alvarez M; Marchou B; Massip P; Wagner T
    Ann Nucl Med; 2014 Feb; 28(2):167-71. PubMed ID: 24203488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
    Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
    Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer.
    Suzuki S; Kaira K; Ohshima Y; Ishioka NS; Sohda M; Yokobori T; Miyazaki T; Oriuchi N; Tominaga H; Kanai Y; Tsukamoto N; Asao T; Tsushima Y; Higuchi T; Oyama T; Kuwano H
    Br J Cancer; 2014 Apr; 110(8):1985-91. PubMed ID: 24667647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
    Vargas HA; Wassberg C; Fox JJ; Wibmer A; Goldman DA; Kuk D; Gonen M; Larson SM; Morris MJ; Scher HI; Hricak H
    Radiology; 2014 Apr; 271(1):220-9. PubMed ID: 24475817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma.
    Kuriyama K; Higuchi T; Yokobori T; Saito H; Yoshida T; Hara K; Suzuki S; Sakai M; Sohda M; Higuchi T; Tsushima Y; Asao T; Kaira K; Kuwano H; Shirabe K; Saeki H
    Cancer Sci; 2020 Jun; 111(6):1969-1978. PubMed ID: 32302443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.